SpringWorks Therapeutics Announces Mirdametinib Data to be Presented at the 2024 Society for Neuro-Oncology (SNO) Annual Meeting
SpringWorks Therapeutics, Inc. - common stock (SWTX)
Last springworks therapeutics, inc. - common stock earnings: 3/12 04:30 pm
Check Earnings Report
Company Research
Source: GlobeNewswire
– Data from the pivotal Phase 2b ReNeu trial demonstrate that patients with NF1-PN achieved deep responses and improvements in health-related quality of life over the course of mirdametinib treatment – – Encouraging results from Phase 1/2 study of mirdametinib in pediatric patients with low-grade glioma also to be presented in oral session at SNO – STAMFORD, Conn., Nov. 11, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that three abstracts from the pivotal Phase 2b ReNeu trial of mirdametinib, an investigational MEK inhibitor, in adults and children with neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN) will be presented in oral and poster sessions at the 29th Annual Meeting & Education Day of the Society for Neuro-Oncology (SNO), being held November 21-24, 2024. ReNeu (NCT03962543) is a multicenter, single-arm trial and the largest
Show less
Read more
Impact Snapshot
Event Time:
SWTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SWTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SWTX alerts
High impacting SpringWorks Therapeutics, Inc. - common stock news events
Weekly update
A roundup of the hottest topics
SWTX
News
- SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) is now covered by analysts at Evercore ISI. They set an "outperform" rating and a $60.00 price target on the stock.MarketBeat
- SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $77.00 price target on the stock.MarketBeat
- Analyst Estimates: Here's What Brokers Think Of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) After Its Third-Quarter Report [Yahoo! Finance]Yahoo! Finance
- SpringWorks' Q3 Loss Narrower Than Expected, Revenues Miss Mark [Yahoo! Finance]Yahoo! Finance
- SpringWorks Therapeutics Inc (SWTX) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... [Yahoo! Finance]Yahoo! Finance
SWTX
Earnings
- 11/12/24 - Beat
SWTX
Sec Filings
- 11/12/24 - Form 10-Q
- 11/12/24 - Form 8-K
- 10/25/24 - Form SC
- SWTX's page on the SEC website